We advise all cancer patients to read this IMPORTANT book about the reality of cancer. CANCER: THE SURPRISING TRUTH. Its author is the prestigious molecular biologist Travis Christofferson. We recommend it for all cancer patients and of course for all physicians and oncologists.
Many of these treatments will require authorization from the Ministry of Health (Spanish Agency for Medicines and Health Products) in order to be administered under the legal figure of ‘COMPASSIONATE USE’.
For this purpose, a dossier will be sent with all the necessary information about the patient, their pathology and the drug to be used, while awaiting authorization for its use.
With authorized checkpoint inhibitors we aim to reduce the abnormal response of the immune system.
Inhibitors do not directly fight cancer cells, but rather help the immune system to more effectively identify cancer cells in order to fight them in any part of the body.
T cells are a type of immune cell that fights cancer; immune checkpoint inhibitors are found on the surface of the cells, controlling the immune response.
In general, immune checkpoints deactivate T cells until they are needed, thus preventing T cells from harming normal cells.
Inhibitors are drugs that block the checkpoints to prevent T cells from attacking the cancer.
The immune checkpoint inhibitors we use are:
- Ipilimumab
- Nivolumab
- Pembrolizumab
Immune checkpoint inhibitors, both in their anti-CTL4 (Ipilimumab) and anti-PD1 (Nivolumab and Pembrolizumab) versions, allow the patient's immune system's executor lymphocytes to act, attacking the tumor cells by inhibiting the immune checkpoints that prevented this lymphocyte action from occurring.
Our protocols use low doses of these drugs on a weekly basis, so that their possible toxicity and side effects are minimal if not non-existent, without reducing their anticancer efficacy.
Request information without obligation
Request information without obligation, we will study your case with our medical team to give you an answer as soon as possible.
